Dan Goldstaub

Dan Goldstaub is an accomplished professional with extensive experience in clinical research and biotechnology. Currently serving as Co-Founder of PhaseV since January 2023, Goldstaub is focused on leveraging AI for clinical trials. As a member of 8400 The Health Network and an entrepreneur at Arkin Holdings, Goldstaub contributes to various health initiatives. Board memberships at Cytora Stem and QRGenetics, along with a speaker role at the Israeli Society for HealthTech, highlight involvement in the healthcare innovation community. Previously, Goldstaub held key leadership positions at MSD, including Executive Director of Clinical Research, overseeing clinical teams across multiple countries. With a strong academic foundation, including a PhD from the Weizmann Institute of Science, Goldstaub combines scientific knowledge with strategic leadership in the healthcare sector.